Kaulanjan Kevin, Lavigne Danny, Saad Fred, Karakiewicz Pierre I, Flammia Rocco Simone, Kluth Luis Alex, Mandel Philipp, Chun Felix K-H, Taussky Daniel, Hoeh Benedikt
Institut du Cancer de Montréal (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC H2X 0A9, Canada.
Department of Urology, Université des Antilles, CHU de Guadeloupe, 97110 Pointe-à-Pitre, France.
Cancers (Basel). 2022 Jul 24;14(15):3606. doi: 10.3390/cancers14153606.
The impact of statin use on localized prostate cancer (PCa) remains controversial, especially for patients treated with radiation therapy. We assessed the impact of statin use on biochemical recurrence (BCR) in patients treated for PCa with different modalities of radiation therapy. We evaluated 3555 patients undergoing radiation therapy between January 2001 and January 2022. The impact of statin use on BCR was analyzed for three treatment groups: external beam radiotherapy (EBRT), low-dose-rate seed brachytherapy (LDR), and EBRT plus high-dose-rate brachytherapy (EBRT + HDR). Median follow-up was 52 months among 1208 patients treated with EBRT, 1679 patients treated with LDR, and 599 patients treated with EBRT + HDR. A total of 1544 (43%) patients were taking a statin at the time of treatment, and 497 (14%) patients were in the D'Amico high-risk group. Only intermediate-risk patients treated with LDR fared better with statin use in univariate analysis ( = 0.025). This association was not significant in multivariate analysis (HR 0.44, 95% CI 0.18-1.10, = 0.06). Statin use was not associated with a reduced risk of BCR in patients treated with radiation therapy. In the era of precision medicine, further investigation is needed to assess the benefit of statins in well-defined patients.
他汀类药物的使用对局限性前列腺癌（PCa）的影响仍存在争议，尤其是对于接受放射治疗的患者。我们评估了他汀类药物的使用对接受不同放射治疗方式的PCa患者生化复发（BCR）的影响。我们评估了2001年1月至2022年1月期间接受放射治疗的3555例患者。分析了三个治疗组中他汀类药物的使用对BCR的影响：外照射放疗（EBRT）、低剂量率粒子植入近距离放疗（LDR）以及EBRT加高剂量率近距离放疗（EBRT + HDR）。接受EBRT治疗的1208例患者、接受LDR治疗的1679例患者以及接受EBRT + HDR治疗的599例患者的中位随访时间为52个月。共有1544例（43%）患者在治疗时正在服用他汀类药物，497例（14%）患者属于达米科高危组。在单因素分析中，仅接受LDR治疗的中危患者使用他汀类药物的效果更好（P = 0.025）。在多因素分析中，这种关联不显著（HR 0.44，95%CI 0.18 - 1.10，P = 0.06）。在接受放射治疗的患者中，他汀类药物的使用与BCR风险降低无关。在精准医学时代，需要进一步研究以评估他汀类药物在明确界定的患者中的益处。
